Tenax Therapeutics, Inc. (TENX) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
4.85
↑+75% vs avg
5yr avg: 2.77
30Y Low0.2·High75.2
ROE
↑
-55.6%
↓+80% vs avg
5yr avg: -273.8%
30Y Low-385%·High-21%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TENX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Tenax Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $543M | $478M | $95M | $5M | $3M | $21M | $14M | $9M | $2M | $14M | $55M |
| Enterprise Value | $445M | $380M | $-319146 | $-3832846 | $2M | $16M | $8M | $4M | $-10595881 | $13M | $45M |
| P/E Ratio → | -8.96 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 4.85 | 4.92 | 1.03 | 0.67 | 2.19 | 5.04 | 2.98 | 2.32 | 0.15 | 1.62 | 3.20 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TENX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
TENX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -55.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -55.6% | -55.6% | -35.2% | -160.8% | -385.1% | -732.2% | -234.6% | -108.0% | -66.0% | -67.9% | -113.3% |
| ROA | -52.4% | -52.4% | -32.5% | -102.2% | -235.1% | -505.0% | -148.9% | -85.2% | -58.7% | -53.2% | -91.2% |
| ROIC | — | — | — | — | — | — | — | — | -154.8% | -95.7% | -123.4% |
| ROCE | -59.6% | -59.6% | -39.0% | -170.6% | -369.3% | -713.2% | -230.0% | -109.7% | -66.8% | -70.8% | -123.1% |
TENX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $98M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.06 | 0.54 | 0.07 | 0.07 | 0.05 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.01 | -1.03 | -1.15 | -0.88 | -1.25 | -1.29 | -1.25 | -1.05 | -0.18 | -0.58 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -764.30 | -320.73 | -2485.58 | -34218.56 | -6053.94 | — | — | — | -1.60 |
Net cash position: cash ($98M) exceeds total debt ($0)
TENX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Tenax Therapeutics, Inc.'s current ratio of 14.56x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.26x to 14.56x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.56 | 14.56 | 20.60 | 3.26 | 1.74 | 3.64 | 3.21 | 2.44 | 8.51 | 7.99 | 2.20 |
| Quick Ratio | 14.56 | 14.56 | 20.60 | 3.26 | 1.74 | 3.64 | 3.21 | 2.44 | 8.51 | 7.99 | 2.20 |
| Cash Ratio | 13.63 | 13.63 | 20.21 | 2.73 | 1.15 | 3.57 | 3.17 | 2.13 | 8.21 | 7.66 | 2.14 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
TENX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Tenax Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 100.0% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $39M | $15M | $248447 | $18391 | $12860 | $4635 | $3872 | $915 | $915 | $879 |
Peer Comparison
Compare TENX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TENXYou | $543M | -9.0 | — | — | — | — | -55.6% | — | — |
 ATHA | $17M | -0.2 | — | — | — | — | -290.8% | — | — |
 NKTR | $1B | -6.3 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 ACAD | $4B | 9.4 | 25.7 | 35.2 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 PRTA | $468M | -2.0 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 IMVT | $7B | -12.8 | — | — | — | — | -64.8% | — | — |
 MDGL | $12B | -39.4 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 ESPR | $655M | -28.6 | 17.1 | — | 67.9% | 15.0% | — | 66.5% | 9.1 |
 RCKT | $366M | -1.7 | — | — | — | — | -60.3% | -62.4% | — |
 ARDX | $1B | -23.3 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 XNCR | $927M | -10.2 | — | — | 91.6% | -141.4% | -14.0% | -16.3% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
TENX — Frequently Asked Questions
Quick answers to the most common questions about buying TENX stock.
What is Tenax Therapeutics, Inc.'s P/E ratio?
Tenax Therapeutics, Inc.'s current P/E ratio is -9.0x. This places it at the 50th percentile of its historical range.
What is Tenax Therapeutics, Inc.'s ROE?
Tenax Therapeutics, Inc.'s return on equity (ROE) is -55.6%. The historical average is -143.0%.
Is TENX stock overvalued?
Based on historical data, Tenax Therapeutics, Inc. is trading at a P/E of -9.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.